ClinicalTrials.gg
Active, not recruitingNCT05445778GLORIOSAUpdated Jun 2, 2026

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

A Phase 3 interventional study of Mirvetuximab soravtansine plus Bevacizumab and Bevacizumab in Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Cancer, sponsored by AbbVie. Active, not recruiting at 264 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. mirvetuximab soravtansine · Ovarian Neoplasms.

Enrollment
Largest of 12
520 · median 80
Started
2023
with 1 other
Phase 3
2 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
4 of 12
AbbVie

Among the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, this one has the largest enrollment, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 7th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About mirvetuximab soravtansine

mirvetuximab soravtansine: first FDA approval 2022 (ELAHERE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, or all of them as a file.
02

Study summary

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Read the detailed description

Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed as maintenance therapy for the treatment of subjects with recurrent platinum-sensitive, highgrade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Patients must have confirmation of FRα positivity by the Ventana FOLR1 Assay.

03

Conditions studied

  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Keywords

  • Platinum-sensitive
  • Folate-receptor alpha expression
  • Antibody-drug conjugate
  • Cancer
  • Ovarian Neoplasma
  • Recurrent Platinum-Sensitive
  • High-Grade Ovarian
  • ADC
  • Adult
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult women >/=18 years old
  2. Confirmed diagnosis of high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer
  3. Confirmed high FRα expression by regulatory-agency approved Ventana FOLR1 (FOLR1-2.1)
  4. disease after frontline () platinum-based chemotherapy and must be plantinum-sensitive
  5. Willing and able to sign the form (ICF) and adhere to protocol requirements
  6. Negative pregnancy test and willing to use highly effective method(s) while on study medication and for at least 7 months after the last dose of MIRV and 6 months after the last dose of bevacizumab

Exclusion criteria

Exclusion Criteria:

  1. Endometrioid, clear cell, mucinous, or sarconmatous histology; mixed tumors containing any of the above or low grade/borderline ovarian tumor
  2. More than one before current/planned triplet therapy
  3. PD (progressive disease) while on or following platinum-based therapy
  4. Prior or whole-pelvis or wide-field radiotherapy
  5. > Grade 1 peripheral neuropathy
  6. History of or concurrent ocular disorders
  7. Grade 4 thromboembolic events
  8. Not appropriate for bevacizumab treatment
  9. Requiring use of folate-containing supplements
  10. Prior to monoclonal antibodies
  11. Pregnant or breatfeeding women
  12. Received prior MIRV or other FRα-targeting agents
  13. Untreated or symptomatic central nervous system
  14. History of other within 3 years prior to signing study consent
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
520 participants (actual)

Study arms

  • Experimental
    Arm 1

    Mirvetuximab Soravtansine (MIRV) plus Bevacizumab

    Drug: Mirvetuximab soravtansine plus Bevacizumab

  • Active comparator
    Arm 2

    Bevacizumab monotherapy

    Drug: Bevacizumab

Interventions

  • DrugMirvetuximab soravtansine plus Bevacizumab

    Drug pages: Mirvetuximab soravtansine · Bevacizumab

    Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks

    Also known as: MIRV

  • Participants will receive Bevacizumab 15mg/kg every 3 weeks

06

What researchers measure

Primary outcomes

  1. Assess Progression-free survival (PFS)

    Progression-free survival defined as assessed by BICR per RECIST v1.1, defined as the time from date of randomization until BICR-assessed PD or death due to any cause, whichever occurs first

    Time frame: Up to 4 years

Secondary outcomes

  1. Assess Overall survival (OS)

    Overall survival (OS), defined as the time from randomization to death

    Time frame: Up to 10 years

  2. Assess Safety and tolerability

    Adverse events (AEs) will be evaluated according to the NCI CTCAE v5

    Time frame: Up to 10 years

  3. Assess time to second disease progression (PFS2)

    Second disease progression (PFS2) defined as the time from date of randomization until second disease progression or death, whichever occurs first

    Time frame: Up to 10 years

  4. Assess Objective Response Rate (ORR)

    Objective response includes best response of complete response (CR) or partial response (PR).

    Time frame: Up to 10 years

  5. Assess Duration of response (DOR)

    DOR as assessed by the investigator and by BICR in patients who have measurable disease per RECIST v1.1 at randomization and achieved a confirmed response of CR or PR after maintenance therapy"

    Time frame: Up to 10 years

  6. Assess Disease-free survival (DFS)

    DOR as assessed by the investigator and by BICR in patients who have no measurable disease per RECIST v1.1 at randomization

    Time frame: Up to 10 years

  7. CA-125 response

    Serum CA-125 response determined using the GCIG criteria

    Time frame: Up to 10 years

  8. Patient-reported outcome health-related quality of life (HRQoL) of disease-related symptoms using the NCCN-FACT Ovarian Symptom Index (NFOSI-18) DRS-P (disease-related symptom subscale - physical).

    A questionnaire assessing the health of patients with ovarian cancer.

    Time frame: Up to 10 years

07

Study locations

264 sites

Showing the first 100 of 264 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • O'Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRalpha-high platinum-sensitive ovarian cancer. Future Oncol. 2024;20(32):2423-2436. doi: 10.1080/14796694.2024.2372241. Epub 2024 Jul 31. PubMed 39082675 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Apr 2027, 49 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 49 months is close to that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 6, 2022
StartActual
Mar 15, 2023
Primary completionEst.
Apr 2027
CompletionEst.
May 2032
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05445778
Lead sponsor
AbbVie
Collaborators
GOG Foundation
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Mar 15, 2023
Primary completion
Apr 2027 (estimated)
Completion
May 2032 (estimated)
Last update
Jun 2, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mirvetuximab soravtansine · Bevacizumab

Start the discussion